Discovery, synthesis, and biological mechanism evaluation of novel quinoline derivatives as potent NLRP3 inhibitors
- 4 March 2025
- journal article
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 289, 117466
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81803364, 81872743)
This publication has 27 references indexed in Scilit:
- Interrogating direct NLRP3 engagement and functional inflammasome inhibition using cellular assaysCell Chemical Biology, 2023
- Discovery of a selective NLRP3-targeting compound with therapeutic activity in MSU-induced peritonitis and DSS-induced acute intestinal inflammationCellular and Molecular Life Sciences, 2023
- Therapeutic potential of MCC950, a specific inhibitor of NLRP3 inflammasomeEuropean Journal of Pharmacology, 2022
- NLRP3 and pyroptosis blockers for treating inflammatory diseasesTrends in Pharmacological Sciences, 2022
- Chloroquine and hydroxychloroquine in antitumor therapies based on autophagy-related mechanismsPharmacological Research, 2021
- Chloroquine/hydroxychloroquine: an inflammasome inhibitor in severe COVID-19?Naunyn-Schmiedeberg's Archives of Pharmacology, 2021
- Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trialThe Lancet Rheumatology, 2020
- NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in miceJournal of Hepatology, 2017
- Hydroxychloroquine concentration–response relationships in patients with rheumatoid arthritisArthritis & Rheumatism, 2002
- Nonpeptide Tachykinin Receptor Antagonists. II. Pharmacological and Pharmacokinetic Profile of SB-222200, a Central Nervous System Penetrant, Potent and Selective NK-3 Receptor AntagonistThe Journal of Pharmacology and Experimental Therapeutics, 2000